Foundation Medicine’s new MET (c-Met) IHC offering helps healthcare providers identify patients eligible for a first-in-class MET-directed antibody drug conjugate (ADC) for NSCLC patients with c ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...

Autoimmune thyroid disease (AITD) causes cellular damage and alters thyroid gland function by humoral and cell-mediated mechanisms. Cellular damage occurs when sensitized T-lymphocytes and/or ...

Visit a quote page and your recently viewed tickers will be displayed here.

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.